Changing Treatment Landscape in Nonmetastatic CRPC

Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.

For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.

Oncologists weigh second-line options after IO/TKI failure in metastatic ccRCC, highlighting tolerability, mechanism shifts, and belzutifan’s broader role.